Reviews/Perioperative Immunotherapy Solid Tumours/Adjuvant immune checkpoint inhibitor benefit is agent-specific in renal cell carcinoma
RCC · PERIO-RCC-02 · v2
This claim says that among immunotherapies given after kidney surgery, only pembrolizumab helps while atezolizumab and the nivolumab-plus-ipilimumab combination do not. The corpus has strong trial data for the first two: pembrolizumab lengthened the time patients stayed free of disease after surgery [1], while atezolizumab did not meet its main disease-free survival goal [11][12]. That difference is real evidence that the drugs behave differently in this setting. But the corpus contains no after-surgery trial of nivolumab plus ipilimumab at all; the only nivolumab-plus-ipilimumab papers here are in advanced or spread disease, not the post-surgery setting [21][22]. The panel also noted that pembrolizumab's survival signal comes from an early look at the data [1]. So one of the three drugs named in the claim is simply not tested here, which is why the panel did not fully endorse it.
Adjuvant pembrolizumab after nephrectomy significantly improved disease-free survival versus placebo (hazard ratio 0.68; 95% CI 0.53 to 0.87; P=0.002), with disease-free survival at 24 months of 77.3% versus 68.1%, and an early overall-survival signal (hazard ratio 0.54; 95% CI 0.30 to 0.96) [1]. Adjuvant atezolizumab did not meet its primary disease-free survival endpoint in the overall trial population (hazard ratio 0.93; 95% CI 0.75 to 1.15; P=0.50) [11][12]. This pembrolizumab-positive versus atezolizumab-negative contrast is the evidentiary core of the agent-specificity thesis. The corpus holds no post-nephrectomy adjuvant trial of nivolumab plus ipilimumab; its nivolumab-plus-ipilimumab papers are advanced or metastatic CheckMate 920 cohorts [21][22], which do not test the adjuvant claim. The contested point: The claim is a three-drug conjunction, but only two drugs are tested in the corpus, so the nivolumab-plus-ipilimumab leg cannot be substantiated here [21][22]. The panel also divided over whether a cross-trial contrast between [1] and [11]/[12] can attribute the divergence to drug identity rather than to differing eligibility, risk definitions and endpoints.
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is a three-agent conjunction, but the corpus contains no primary adjuvant trial of nivolumab plus ipilimumab after nephrectomy (CheckMate 914); [21] and [22] are metastatic CheckMate 920, so the nivo+ipi leg is wholly unevidenced and the full claim cannot be confirmed.
Pembrolizumab's OS benefit in [1] is an interim secondary endpoint with a confidence interval (0.30-0.96) brushing unity; the claim asserts an OS benefit more firmly than the single immature result supports.
Where it remains uncertain. The third named regimen, nivolumab plus ipilimumab, has no adjuvant trial in this corpus; [21] and [22] are advanced/metastatic CheckMate 920, and pembrolizumab's overall-survival signal is an interim secondary result [1].
Aleatory
Pembrolizumab's overall-survival estimate (hazard ratio 0.54; 95% CI 0.30 to 0.96) comes from a prespecified interim analysis and its interval brushes unity [1].
Epistemic
The corpus contains no post-nephrectomy adjuvant trial of nivolumab plus ipilimumab; [21] and [22] test advanced/metastatic disease, leaving one leg of the claim untested here.
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes the pembrolizumab DFS benefit in adjuvant RCC after nephrectomy
“The estimated percentage of patients who remained alive at 24 months was 96.6% in the pembrolizumab group and 93.5% in the placebo group (hazard ratio for death, 0.54; 95% CI, 0.30 to 0.96).”
Panel auditInternal validity: high · scope of inference: Clear-cell RCC patients at high risk of recurrence after nephrectomy, DFS and interim OS.Key limitations: interim OS, median follow-up 24.1 months · single agent only, no cross-agent comparison
Establishes that adjuvant atezolizumab did not improve DFS, supporting the atezolizumab-negative leg
“This trial did not meet its primary endpoint of disease-free survival (DFS) in the intention-to-treat population.”
Panel auditInternal validity: high · scope of inference: Adjuvant atezolizumab in resected RCC at increased risk of recurrence, DFS.Key limitations: KIM-1-high subgroup showed benefit (HR 0.72, exploratory) · biomarker analysis, OS not the focus
Quantifies the null atezolizumab adjuvant result (HR 0.93, P=0.50)
“In IMmotion010, adj atezo did not prolong investigator-assessed disease-free survival (DFS; primary endpoint) vs pbo after resection in pts with RCC (HR: 0.93, 95% CI: 0.75, 1.15; P=0.50; Pal Lancet 2023).”
Panel auditInternal validity: medium · scope of inference: Adjuvant atezolizumab in resected RCC at increased recurrence risk, DFS.Key limitations: conference abstract · KIM-1-high subgroup showed differential benefit (exploratory)
3 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Two of three named agents are directly and robustly covered in the claimed directions, but the missing nivo+ipi primary trial and the immature OS data cap confidence in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adjuvant nivolumab plus ipilimumab after nephrectomy. The entire third leg of the agent-specific claim is untested in this corpus; without it the conjunction cannot be confirmed [21][22]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized placebo-controlled adjuvant trial of nivolumab plus ipilimumab in resected high-risk RCC with disease-free and overall survival endpoints.
Open question: Does adjuvant nivolumab plus ipilimumab improve disease-free or overall survival after nephrectomy in high-risk RCC? Why it is still open: The corpus contains no adjuvant trial of this regimen; [21] and [22] are advanced/metastatic CheckMate 920 cohorts only.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19